Base Editor Restores Glucose Production in GSDIa Patients
Interested in hosting a webinar on CMN?
Contact us to learn more about our CMN Webinars package.
+35k readers | +35k followers | Top-1 CRISPR News Site | sales@crisprmedicinenews.com | Webinars
Glycogen storage disease type Ia, or GSDIa, is caused by biallelic mutations in G6PC1, which encodes glucose-6-phosphatase. The enzyme performs a final step in releasing glucose made from stored glycogen or other substrates. When it is deficient, blood glucose can fall rapidly between meals, leaving patients at risk of seizures, loss of consciousness and death.
People carrying the severe R83C variant may become hypoglycaemic within one to three hours without food or uncooked cornstarch, which releases glucose slowly. Treatment therefore requires repeated starch doses, including overnight. R83C is one of the most prevalent disease-causing mutations in the condition and is associated with its most severe form. No approved therapy addresses the cause.
BEAM-301 is a liver-targeting lipid-nanoparticle formulation of base editing reagents, developed by Beam Therapeutics. Base editors are CRISPR-CAS-derived enzymes that convert one base pair into another at a defined position without cutting both strands of the DNA, and the intention here is to restore the correct codon at position 83 rather than to add a gene copy or silence a downstream pathway. The candidate is being assessed in an open-label Phase 1/2 dose-exploration and dose-expansion trial with endpoints covering safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy.
In a company press release from 13 October, Amy Simon, chief medical officer at Beam, says the initial data are the first clinical evidence that the therapy restored endogenous glucose production after a single in vivo treatment, and calls the result "an important proof of concept" for precision genetic medicines tailored to a patient's specific mutation. The numbers behind that claim are early, and their asymmetry is the first thing to note.
As of the data cutoff on 26 June 2026, six patients had received a single intravenous infusion, three at 20 mg and three at 40 mg. Median follow-up was 313 days in the 20 mg cohort, with a range of 249 to 453 days, and 53 days in the 40 mg cohort, with a range of 5 to 110 days. One patient in the higher-dose cohort was not evaluable for efficacy at the cutoff, leaving only two evaluable patients at that dose.
The clearest pharmacodynamic signal was an increase in time to fasting hypoglycaemia. Median fasting tolerance rose from 2.9 hours at baseline to 4.3 hours by day 36 in the 20 mg group. Both evaluable patients in the 40 mg group reached the protocol-defined ceiling of at least 15 hours at day 36, a result that the company interpreted as evidence of restored endogenous glucose production. The dose pattern is encouraging, but the tiny cohorts, open-label design and capped fasting test prevent firm estimates of the magnitude or durability of benefit.
Cornstarch doses drop, but the effect may not last a year
Prescribed starch use also fell, although the individual responses varied. In the 20 mg group, reductions from baseline were 74% at day 128, 71% at day 227 but remarkably only 11% at day 387. The two evaluable patients in the 40 mg group had reductions of 71% at day 50 and 92% at day 93. Patients reduced their daily dosing frequency by zero to four doses at 20 mg and by two to four doses at 40 mg. Triglyceride concentrations, another metabolic feature of GSDIa, were comparable with baseline at the latest follow-up.
Safety findings will be important because the treatment edits liver cells in vivo and cannot simply be withdrawn after dosing. Every participant had at least one treatment-emergent adverse event considered related to BEAM-301. Five serious adverse events were reported, including three grade 3 infusion-related reactions; all resolved within two to ten days.
Beam said that shorter-acting steroid premedication may have contributed to the reactions and that the regimen has since been changed. Liver-enzyme elevations were transient and resolved without intervention. There were no reported dose-limiting toxicities, treatment discontinuations caused by adverse events or deaths.
The findings therefore provide an early clinical signal that mutation-specific base editing can alter the physiology of GSDIa after a single treatment. They do not yet establish long-term efficacy or safety, and the high-dose observations rest on two patients with relatively short follow-up.
In the press release, Simon acknowledged that “While follow-up remains ongoing”, and updated data due at the ESGCT meeting will be needed to judge whether fasting tolerance and reduced starch dependence persist, whether responses are consistent across more patients, and whether adverse reactions can be controlled as dosing expands.
The data was presented in a Beam Therapeutics press release on 13 October 2026. Additional data is scheduled for presentation as poster P0219 at the 33rd Annual Congress of the European Society of Gene and Cell Therapy in Hamburg on 28 October 2026.
To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.
Tags
ArticleCMN HighlightsNewsClinical News UpdatesLipid-based nanoparticleGlycogen storage diseaseMetabolic disordersBase editorsBeam Therapeutics Inc.Clinical












